Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Lenalidomide works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving venetoclax, glofitamab with obinutuzumab, and lenalidomide together may kill more cancer cells in patients with newly diagnosed, high risk mantle cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 80 lat
- •Potwierdzona diagnoza chłoniaka płaszcza na podstawie badania próbki tkanki
- •Obecność zmian genetycznych charakterystycznych dla chłoniaka płaszcza (translokacja t(11;14) lub ekspresja cyclin D1)
- •Chłoniak należący do kategorii wysokiego ryzyka (np. typ blastoidalny, wysoki wskaźnik Ki67, mutacja TP53)
- •Nigdy wcześniej nie otrzymywał chemioterapii lub innych leków przeciwnowotworowych
- •Zdolność do przełykania tabletek
- •Odpowiedni stan ogólny (ECOG 0-2)
- •Wystarczająca liczba białych krwinek we krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
City of Hope Medical Center
Duarte, United States
Mount Sinai School of Medicine
New York, United States
Huntsman Cancer Institute
Salt Lake City, United States
Trial contact
Tycel J. Phillips
Tycel J. Phillips
PRINCIPAL_INVESTIGATOR
Joshua Brody
Daniel Ermann, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.